Annual Report 2017

April 16, 2018

What to Expect from This Document?

Better known up until a few years ago for its bioseparation and enabling of manufacturing of biopharmaceuticals expertise, Prometic has during 2017, continued its transition that has transformed the company into a biopharmaceutical corporation with two drug discovery platforms focusing on rare and orphan diseases representing significant and unmet medical needs.

Previous Flipbook
Quarterly Report 2018 Q3
Quarterly Report 2018 Q3

Next Flipbook
2016 Annual Report
2016 Annual Report

Prometic is only months away from becoming a fully integrated biopharmaceutical company.